JP3681729B2 - 塩基置換の検出方法 - Google Patents
塩基置換の検出方法 Download PDFInfo
- Publication number
- JP3681729B2 JP3681729B2 JP2002565143A JP2002565143A JP3681729B2 JP 3681729 B2 JP3681729 B2 JP 3681729B2 JP 2002565143 A JP2002565143 A JP 2002565143A JP 2002565143 A JP2002565143 A JP 2002565143A JP 3681729 B2 JP3681729 B2 JP 3681729B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- base
- nucleic acid
- detecting
- base substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000037429 base substitution Effects 0.000 title claims abstract description 155
- 238000001514 detection method Methods 0.000 title description 76
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 275
- 239000002773 nucleotide Substances 0.000 claims abstract description 253
- 238000000034 method Methods 0.000 claims abstract description 127
- 150000007523 nucleic acids Chemical class 0.000 claims description 118
- 108020004707 nucleic acids Proteins 0.000 claims description 117
- 102000039446 nucleic acids Human genes 0.000 claims description 117
- 238000006243 chemical reaction Methods 0.000 claims description 113
- 101710163270 Nuclease Proteins 0.000 claims description 64
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 51
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 51
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 39
- 230000003321 amplification Effects 0.000 claims description 33
- 238000003776 cleavage reaction Methods 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 29
- 230000007017 scission Effects 0.000 claims description 28
- 102100034343 Integrase Human genes 0.000 claims description 22
- 101710203526 Integrase Proteins 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 19
- 108700028369 Alleles Proteins 0.000 claims description 18
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims description 13
- 108091028664 Ribonucleotide Proteins 0.000 claims description 12
- 239000002336 ribonucleotide Substances 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 10
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 230000000171 quenching effect Effects 0.000 claims description 6
- 238000002875 fluorescence polarization Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 19
- 108700026220 vif Genes Proteins 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 82
- 239000000243 solution Substances 0.000 description 62
- 239000013615 primer Substances 0.000 description 59
- 239000000523 sample Substances 0.000 description 44
- 239000000047 product Substances 0.000 description 39
- 108090000731 ribonuclease HII Proteins 0.000 description 37
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000004544 DNA amplification Effects 0.000 description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 102000054765 polymorphisms of proteins Human genes 0.000 description 7
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000205156 Pyrococcus furiosus Species 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 102000019057 Cytochrome P-450 CYP2C19 Human genes 0.000 description 5
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 5
- 101710113436 GTPase KRas Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 108010068698 spleen exonuclease Proteins 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000205042 Archaeoglobus fulgidus Species 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101000919361 Homo sapiens Cytochrome P450 2C19 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000203353 Methanococcus Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 241000522615 Pyrococcus horikoshii Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 241000589596 Thermus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 102000057376 human CYP2C19 Human genes 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000205188 Thermococcus Species 0.000 description 1
- 241000204652 Thermotoga Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000193758 [Bacillus] caldotenax Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000007281 aminoalkylation reaction Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 108010041758 cleavase Proteins 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003290 ribose derivatives Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- -1 that is Proteins 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001039268 | 2001-02-15 | ||
| JP2001039268 | 2001-02-15 | ||
| JP2001040721 | 2001-02-16 | ||
| JP2001040721 | 2001-02-16 | ||
| JP2001101055 | 2001-03-30 | ||
| JP2001101055 | 2001-03-30 | ||
| JP2001177381 | 2001-06-12 | ||
| JP2001177381 | 2001-06-12 | ||
| JP2001290384 | 2001-09-25 | ||
| JP2001290384 | 2001-09-25 | ||
| JP2001338440 | 2001-11-02 | ||
| JP2001338440 | 2001-11-02 | ||
| JP2001368929 | 2001-12-03 | ||
| JP2001368929 | 2001-12-03 | ||
| PCT/JP2002/001222 WO2002064833A1 (en) | 2001-02-15 | 2002-02-14 | Method of detecting nucleotide polymorphism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004221749A Division JP2004298200A (ja) | 2001-02-15 | 2004-07-29 | 塩基置換の検出方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2002064833A1 JPWO2002064833A1 (ja) | 2004-06-17 |
| JP3681729B2 true JP3681729B2 (ja) | 2005-08-10 |
Family
ID=27567022
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565143A Expired - Fee Related JP3681729B2 (ja) | 2001-02-15 | 2002-02-14 | 塩基置換の検出方法 |
| JP2004221749A Pending JP2004298200A (ja) | 2001-02-15 | 2004-07-29 | 塩基置換の検出方法 |
| JP2005144399A Pending JP2005245465A (ja) | 2001-02-15 | 2005-05-17 | 塩基置換の検出方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004221749A Pending JP2004298200A (ja) | 2001-02-15 | 2004-07-29 | 塩基置換の検出方法 |
| JP2005144399A Pending JP2005245465A (ja) | 2001-02-15 | 2005-05-17 | 塩基置換の検出方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7135291B2 (enExample) |
| EP (1) | EP1367136A4 (enExample) |
| JP (3) | JP3681729B2 (enExample) |
| KR (1) | KR100809949B1 (enExample) |
| CN (1) | CN100351393C (enExample) |
| AU (1) | AU2002232177B2 (enExample) |
| CA (1) | CA2438574C (enExample) |
| EA (1) | EA005141B1 (enExample) |
| WO (1) | WO2002064833A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200404889A (en) * | 2002-05-31 | 2004-04-01 | Takara Bio Inc | Method of typing gene polymorphisms |
| WO2006137733A1 (en) * | 2005-06-23 | 2006-12-28 | Keygene N.V. | Strategies for high throughput identification and detection of polymorphisms |
| EP2644707B1 (en) * | 2008-04-30 | 2015-06-03 | Integrated Dna Technologies, Inc. | RNase-H-based assays utilizing modified RNA monomers |
| WO2014143228A1 (en) * | 2013-03-15 | 2014-09-18 | Integrated Dna Technologies, Inc. | Rnase h-based assays utilizing modified rna monomers |
| US10227641B2 (en) | 2008-04-30 | 2019-03-12 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| US8911948B2 (en) | 2008-04-30 | 2014-12-16 | Integrated Dna Technologies, Inc. | RNase H-based assays utilizing modified RNA monomers |
| WO2010026933A1 (ja) * | 2008-09-03 | 2010-03-11 | タカラバイオ株式会社 | Ｒｎａ検出用組成物 |
| EP2337865B1 (en) * | 2008-10-20 | 2014-11-19 | Roche Diagnostics GmbH | Allele-specific amplification using a primer with a modified nucleotide |
| WO2011060014A1 (en) * | 2009-11-13 | 2011-05-19 | Integrated Dna Technologies, Inc. | Small rna detection assays |
| US8614071B2 (en) | 2009-12-11 | 2013-12-24 | Roche Molecular Systems, Inc. | Preferential amplification of mRNA over DNA using chemically modified primers |
| US9238832B2 (en) | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
| WO2012135053A2 (en) | 2011-03-25 | 2012-10-04 | Integrated Dna Technologies, Inc. | Rnase h-based assays utilizing modified rna monomers |
| WO2013123238A1 (en) | 2012-02-14 | 2013-08-22 | Great Basin Scientific | Methods of isothermal amplification using blocked primers |
| KR102126744B1 (ko) | 2013-03-14 | 2020-06-26 | 다카라 바이오 가부시키가이샤 | 내열성 미스매치 엔도뉴클레아제의 이용방법 |
| CA2930595C (en) | 2013-11-14 | 2023-09-19 | Integrated Dna Technologies, Inc. | Dna polymerase mutants having enhanced template discrimination activity |
| EP3825411A1 (en) | 2014-06-18 | 2021-05-26 | Clear Gene, Inc. | Methods, compositions, and devices for rapid analysis of biological markers |
| KR20170053636A (ko) | 2014-09-11 | 2017-05-16 | 다카라 바이오 가부시키가이샤 | 내열성의 미스매치 엔도뉴클레아제의 이용방법 |
| US9909169B2 (en) | 2014-12-17 | 2018-03-06 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression |
| JP6914831B2 (ja) * | 2015-03-20 | 2021-08-04 | タカラバイオ株式会社 | 標的核酸の高感度検出方法 |
| US11401558B2 (en) | 2015-12-18 | 2022-08-02 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| US12275994B2 (en) | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| CN108148895A (zh) * | 2017-12-29 | 2018-06-12 | 星阵（广州）基因科技有限公司 | 用于检测突变的人akt1基因的引物、试剂盒及方法 |
| WO2022169846A1 (en) * | 2021-02-02 | 2022-08-11 | Rhodx, Inc. | Synthetic polynucleotides and methods for selectively amplifying alleles |
| CN113215163B (zh) * | 2021-05-12 | 2023-05-12 | 苏州海苗生物科技有限公司 | 一种特异性扩增目的基因的分子锁及应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521509A (en) | 1982-11-24 | 1985-06-04 | Research Corporation | Method for degrading DNA |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5011769A (en) | 1985-12-05 | 1991-04-30 | Meiogenics U.S. Limited Partnership | Methods for detecting nucleic acid sequences |
| US4876187A (en) | 1985-12-05 | 1989-10-24 | Meiogenics, Inc. | Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| JP2650159B2 (ja) | 1988-02-24 | 1997-09-03 | アクゾ・ノベル・エヌ・ベー | 核酸増幅方法 |
| US5639611A (en) * | 1988-12-12 | 1997-06-17 | City Of Hope | Allele specific polymerase chain reaction |
| US5137806A (en) | 1989-12-11 | 1992-08-11 | Board Of Regents, The University Of Texas System | Methods and compositions for the detection of sequences in selected DNA molecules |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| WO1995014106A2 (en) * | 1993-11-17 | 1995-05-26 | Id Biomedical Corporation | Cycling probe cleavage detection of nucleic acid sequences |
| ATE206764T1 (de) | 1994-07-16 | 2001-10-15 | Roche Diagnostics Gmbh | Verfahren zum sensitiven nachweis von nukleinsäuren |
| CA2243353C (en) * | 1996-01-24 | 2010-03-30 | Third Wave Technologies, Inc. | Invasive cleavage of nucleic acids |
| NL1002427C2 (nl) * | 1996-02-23 | 1997-08-26 | Akzo Nobel Nv | Bekledingssamenstelling omvattende een bicyclo- of spiroorthoester functionele verbinding. |
| US5808108A (en) * | 1997-01-15 | 1998-09-15 | Chappelow; Cecil C. | Polymeric compositions and composites prepared from spiroorthocarbonates and epoxy monomers |
| DE19733619C1 (de) | 1997-08-04 | 2000-02-24 | Markus Schuermann | CASE-PCR, ein hochselektives Verfahren zum Nachweis von Onkogenmutationen und Allelvarianten |
| EA004327B1 (ru) | 1999-03-19 | 2004-04-29 | Такара Био. Инк. | Способ амплификации последовательности нуклеиновой кислоты |
| GB9915200D0 (en) * | 1999-06-29 | 1999-09-01 | Janssen Pharmaceutica Nv | Neurotrophic factor receptor |
| CA2377780A1 (en) | 1999-07-02 | 2001-01-11 | Invitrogen Corporation | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| GB9918150D0 (en) | 1999-08-03 | 1999-10-06 | Univ Sheffield | Nuclease variant |
| US6274353B1 (en) | 1999-09-22 | 2001-08-14 | Genecopoeia, Inc. | Method and compositions for improved polynucleotide synthesis |
| JP2001136965A (ja) | 1999-11-12 | 2001-05-22 | Takara Shuzo Co Ltd | 核酸配列の増幅方法 |
| EP1241266A4 (en) | 1999-12-10 | 2004-11-17 | Toyo Boseki | METHOD FOR DETECTING NUCLEIC ACID POLYMORPHISMS |
| DE60141087D1 (de) | 2000-06-26 | 2010-03-04 | Nugen Technologies Inc | Methoden und zusammensetzungen zur auf transkription basierenden vervielfältigung von nukleinsäuren |
| US6773885B1 (en) * | 2000-09-29 | 2004-08-10 | Integrated Dna Technologies, Inc. | Compositions and methods for visual ribonuclease detection assays |
| WO2002063049A2 (en) * | 2001-02-02 | 2002-08-15 | Genome Therapeutics Corporation | Methods for determining a nucleotide at a specific location within a nucleic acid molecule |
| AU2002351193A1 (en) * | 2001-11-28 | 2003-06-10 | Mj Bioworks Incorporated | Parallel polymorphism scoring by amplification and error correction |
-
2002
- 2002-02-14 CN CNB028079310A patent/CN100351393C/zh not_active Expired - Fee Related
- 2002-02-14 KR KR1020037010391A patent/KR100809949B1/ko not_active Expired - Fee Related
- 2002-02-14 CA CA002438574A patent/CA2438574C/en not_active Expired - Fee Related
- 2002-02-14 AU AU2002232177A patent/AU2002232177B2/en not_active Ceased
- 2002-02-14 US US10/468,128 patent/US7135291B2/en not_active Expired - Fee Related
- 2002-02-14 EA EA200300880A patent/EA005141B1/ru not_active IP Right Cessation
- 2002-02-14 JP JP2002565143A patent/JP3681729B2/ja not_active Expired - Fee Related
- 2002-02-14 WO PCT/JP2002/001222 patent/WO2002064833A1/ja not_active Ceased
- 2002-02-14 EP EP02712338A patent/EP1367136A4/en not_active Withdrawn
-
2004
- 2004-07-29 JP JP2004221749A patent/JP2004298200A/ja active Pending
-
2005
- 2005-05-17 JP JP2005144399A patent/JP2005245465A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002064833A1 (en) | 2002-08-22 |
| JP2005245465A (ja) | 2005-09-15 |
| CN100351393C (zh) | 2007-11-28 |
| US20040137451A1 (en) | 2004-07-15 |
| CA2438574C (en) | 2009-08-11 |
| EA005141B1 (ru) | 2004-12-30 |
| EA200300880A1 (ru) | 2004-02-26 |
| JPWO2002064833A1 (ja) | 2004-06-17 |
| JP2004298200A (ja) | 2004-10-28 |
| KR20030074797A (ko) | 2003-09-19 |
| KR100809949B1 (ko) | 2008-03-06 |
| EP1367136A4 (en) | 2005-01-12 |
| AU2002232177B2 (en) | 2006-11-09 |
| CA2438574A1 (en) | 2002-08-22 |
| CN1524127A (zh) | 2004-08-25 |
| EP1367136A1 (en) | 2003-12-03 |
| US7135291B2 (en) | 2006-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3681729B2 (ja) | 塩基置換の検出方法 | |
| TWI257426B (en) | Nucleic acid amplification methods | |
| AU704625B2 (en) | Method for characterizing nucleic acid molecules | |
| ES2375764T3 (es) | Endonucleasas fen-1, mezclas y procedimientos de escisión. | |
| JP6216416B2 (ja) | 耐熱性のミスマッチエンドヌクレアーゼの利用方法 | |
| KR20110138387A (ko) | Ｆｍｒ１ 및 ｆｍｒ２ 유전자의 ５´ 비번역 영역을 규명하기 위한 ｐｃｒ 방법 | |
| JPH08505535A (ja) | 一本鎖ｄｎａ分子の生成方法 | |
| EP0823479A2 (en) | Modified thermostable DNA polymerase | |
| CN101778952A (zh) | 使用寡核苷酸和显著缺乏5′-3′核酸外切酶活性的聚合酶抑制扩增 | |
| WO2005063977A1 (ja) | 核酸の増幅法およびこれを利用した変異核酸の検出法 | |
| CN109251907A (zh) | 基因突变特异性扩增效率提高的dna聚合酶 | |
| CN109251965A (zh) | 一种具有增加的基因突变特异性的dna聚合酶活性增强用pcr缓冲液组合物 | |
| JP2014079237A (ja) | 改変された耐熱性ｄｎａポリメラーゼ | |
| MX2015000766A (es) | Sondas, cebadores cooperativos y aplicaciones de ellos. | |
| Zhang et al. | Single-base discrimination mediated by proofreading 3′ phosphorothioate-modified primers | |
| US20060199178A1 (en) | Method of typing gene polymorphisms | |
| JP6074036B2 (ja) | 拡大された基質範囲を有する新規のｄｎａポリメラーゼ | |
| JPWO2008066163A1 (ja) | Ｃｙｐ２ｃ９遺伝子増幅用プライマーセット、それを含むｃｙｐ２ｃ９遺伝子増幅用試薬およびその用途 | |
| JPWO2008066161A1 (ja) | Ｎａｔ２遺伝子増幅用プライマーセット、それを含むｎａｔ２遺伝子増幅用試薬およびその用途 | |
| JP4019171B2 (ja) | 誤対合修復系を利用したｄｎａの解析方法および操作方法 | |
| ES2383990T3 (es) | Endonucleasas FEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20040426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040729 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050406 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050510 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050518 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090527 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090527 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110527 Year of fee payment: 6 |
|
| LAPS | Cancellation because of no payment of annual fees |